The PLK-1 inhibitors market is experiencing robust growth driven by increasing investments in cancer research and the expanding pipeline of novel therapeutic agents. The rising prevalence of cancer and demand for targeted therapies are fueling market expansion. Additionally, advancements in clinical trials and rising collaborations between pharmaceutical companies are further propelling the market forward.
LAS VEGAS , Oct. 1, 2024 /PRNewswire/ -- DelveInsight's PLK-1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PLK-1 inhibitors, market share of individual therapies, and current and forecasted PLK-1 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the PLK-1 Inhibitors Market Report As per DelveInsight's analysis, the total market size of PLK-1 inhibitors in the 7MM is expected to surge significantly by 2034.
Leading PLK-1 inhibitor companies such as Cardiff Oncology, Notable Labs, Cyclacel Pharmaceuticals, and others are developing novel PLK-1 inhibitors that can be available in the PLK-1 inhibitors market in the coming years. Some of the key PLK-1 inhibitors in the pipeline include Onvansertib, Volasertib (NBL-001, BI 6727), Plogosertib (CYC140) , and others. In 2019, Oncoheroes Biosciences and Boehringer Ingelheim signed an exclusive licensing agreement for volasertib.
Mor.
